Cancer and necroptosis: friend or foe?

被引:63
|
作者
Philipp, Stephan [1 ]
Sosna, Justyna [1 ]
Adam, Dieter [1 ]
机构
[1] Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany
关键词
Regulated necrosis; Necroptosis; Cancer; TRAIL; TNF; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; TRAIL RECEPTOR; TNF-ALPHA; APOPTOSIS; RIP3; EXPRESSION; FADD;
D O I
10.1007/s00018-016-2193-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regulated cell death is one major factor to ensure homoeostasis in multicellular organisms. For decades, apoptosis was considered as the sole form of regulated cell death, whereas necrosis was believed to be accidental and unregulated. Due to this view, research on necrosis was somewhat neglected, especially in the field of anti-cancer treatment. However, new interest in necrosis has been sparked by the recent discovery of different forms of necrosis that show indeed regulated pathways. More and more studies now address the molecular pathways of regulated necrosis and its connections within the cellular signaling networks. Necroptosis, a subform of regulated necrosis, has so far hardly been focused on with regard to a future treatment of cancer patients and may emerge as a novel and effective approach to eliminate tumor cells. However, and similar to apoptosis, tumor cells can develop resistances against necroptosis to ensure their own survival. In this context, new molecules that enhance necroptosis are currently being identified to overcome such resistances. This review discusses cancer and necroptosis as friends or foes, i.e. the options to exploit necroptosis in anti-cancer therapies ("foes"), but also potential limitations that may block or actually cause necroptosis to act in a protumoral manner ("friends"). The balance between these two possible roles will determine whether necroptosis can indeed be used as a promising tool for early diagnosis of tumors, prevention of metastasis and anti-cancer treatment.
引用
收藏
页码:2183 / 2193
页数:11
相关论文
共 50 条
  • [31] Targeting CREB for Cancer Therapy: Friend or Foe
    Xiao, X.
    Li, B. X.
    Mitton, B.
    Ikeda, A.
    Sakamoto, K. M.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (04) : 384 - 391
  • [32] ARID1A in cancer: Friend or foe?
    Fontana, Beatrice
    Gallerani, Giulia
    Salamon, Irene
    Pace, Ilaria
    Roncarati, Roberta
    Ferracin, Manuela
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] The dichotomous role of immunoproteasome in cancer: Friend or foe?
    Chen, Boya
    Zhu, Haiying
    Yang, Bo
    Cao, Ji
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (05) : 1976 - 1989
  • [34] Cancer germline gene activation Friend or foe?
    McFarlane, Ramsay J.
    Feichtinger, Julia
    Larcombe, Lee
    CELL CYCLE, 2014, 13 (14) : 2151 - 2152
  • [35] The Role of A20 in Cancer: Friend or Foe?
    Lee, Jinju
    Cheong, Heesun
    CELLS, 2025, 14 (07)
  • [36] Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
    Jensen, Agnete Witness Praest
    Simoes, Ana Micaela Carnaz
    Straten, Per Thor
    Olofsson, Gitte Holmen
    CANCERS, 2021, 13 (03) : 1 - 16
  • [37] The Human Microbiota and Prostate Cancer: Friend or Foe?
    Massari, Francesco
    Mollica, Veronica
    Di Nunno, Vincenzo
    Gatto, Lidia
    Santoni, Matteo
    Scarpelli, Marina
    Cimadamore, Alessia
    Lopez-Beltran, Antonio
    Cheng, Liang
    Battelli, Nicola
    Montironi, Rodolfo
    Brandi, Giovanni
    CANCERS, 2019, 11 (04)
  • [38] 17β-estradiol in colorectal cancer: friend or foe?
    Wu, Zihong
    Xiao, Chong
    Wang, Jiamei
    Zhou, Min
    You, Fengming
    Li, Xueke
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [39] RGS proteins and their roles in cancer: friend or foe?
    Li, Lin
    Xu, Qiang
    Tang, Chao
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [40] Autophagy: cancer therapy's friend or foe?
    Grander, Dan
    Panaretakis, Theocharis
    FUTURE MEDICINAL CHEMISTRY, 2010, 2 (02) : 285 - 297